Beijing Pearl Biotechnology Limited Liability Company
Quick facts
Phase 3 pipeline
- PLB1001 · Oncology
PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Beijing Pearl Biotechnology Limited Liability Company portfolio CI brief
- Beijing Pearl Biotechnology Limited Liability Company pipeline updates RSS
Frequently asked questions about Beijing Pearl Biotechnology Limited Liability Company
What is Beijing Pearl Biotechnology Limited Liability Company's pipeline?
Beijing Pearl Biotechnology Limited Liability Company has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include PLB1001.
Related
- Sector hub: All tracked pharma companies